Portfolio Highlights: Clinical and Financing Updates of VivaVision, QureBio, AlxplorerBio and BIOCAST
VivaVision Announces the Establishment of Scientific Advisory Board and the First Patient Enrollment in Phase II Clinical Trials of VVN001 in China
VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator, announced the establishment of Scientific Advisory Board (SAB) and the first SAB meeting was successfully held. The SAB aims to provide in-depth suggestions for the continuous development of innovative ophthalmic drugs.
Additionally, VivaVision announced that the company had completed the first patient enrollment and dose in phase II clinical trials of LFA1 Inhibitor VVN001, a novel drug for dry eye disease treatment, in China. VVN001 is an innovative LFA1 inhibitor drug independently developed by VivaVision, and it is also the first project to enter the clinical stage in a series of ophthalmic innovative drug pipeline of the company.
QureBio Completed Nearly 200 Million RMB in Series B
December 2021, QureBio, invested and incubated by Viva BioInnovator, who is dedicated to the development of innovative antibody drugs, announced it has successfully completed nearly 200 Million RMB in Series B. The round was led by BOCOM International Holdings. Other investors who joined the round include Guoshun Investment, Oriza Holdings, Lihe Hongxin Venture Investment, Tianfu Sanjiang Capital, Spinnotec and Longmen Capital.
AlxplorerBio and AliveX, BIOCAST Reached a Strategic Collaboration Agreement, To Jointly Promote the Development of Precision Medicines of IBD
Shanghai, China - December 23, AlxplorerBio, invested and incubated by Viva BioInnovator, announced that a strategic collaboration with AliveX and BIOCAST(invested and incubated by Viva BioInnovator) to promote the development of precision medicines of Inflammatory Bowel Disease (IBD). The collaboration integrates the strengths of the three companies to jointly promote the development of precision medicines of IBD, preclinical studies, and IND enabling in China and the U.S.